美国Xoma
美国Xoma成立于1981年，是一家生物制药公司发现，开发和制造用于治疗炎症，自身免疫，传染性疾病和肿瘤治疗性抗体的重点。

XOMA Ltd. (XOMA), incorporated in 1981, is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company’s product development pipeline includes XOMA 052, an anti-interleukin-1 beta (IL-1 beta) antibody, XOMA 3AB, a biodefense anti-botulism antibody candidate, and preclinical antibody discovery programs in several indications. XOMA have an integrated product development platform, extending from preclinical science to development and manufacturing. The Company’s technologies have contributed to the success of marketed antibody products, including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn’s disease.

XOMA 052 is a monoclonal antibody with the potential to improve the treatment of patients with a range of inflammatory diseases. XOMA 052 binds the IL-1 beta, a pro-inflammatory cytokine involved in the development of Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and other diseases. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. XOMA 052 is a humanized IgG2 antibody with a half-life of 22 days. Based on its binding properties, specificity to IL-1 beta and half-life, XOMA 052 may provide convenient dosing of once per month or less frequently.

During the year ended December 31, 2009, the Company announced the initiation of the Phase II clinical program for XOMA 052 in Type 2 diabetes, Type 1 diabetes and cardiovascular disease. The clinical trials are designed to further evaluate the use of multiple dose regimens on the safety, pharmacodynamics and efficacy of XOMA 052 in cardiometabolic and other diseases, and based on positive results, select doses for pivotal Phase III studies.

XOMA 3AB is a multi-antibody product designed to neutralize the potent of the botulinum toxins, Type A, which causes paralysis and is a bioterrorism threat. The anti-botulism program was expanded to include additional product candidates. It combines multiple human antibodies to focus a range of broad spectrum of the toxic botulinum toxins, including the three toxic serotypes of botulism, Types A, B and E. The antibodies are designed to bind to each toxins and improve the clearance of the toxin from the body. The use of multiple antibodies increases the likelihood of clearing the harmful toxins by providing specific protection against each toxin type. In contrast to existing agents that treat botulism, XOMA uses advanced human monoclonal antibody technologies in an effort to achieve safety, potency and efficacy, and avoid life threatening immune reactions associated with animal-derived products. XOMA 3AB is in the pre-investigational new drug (IND) stage, and in the nonclinical studies to assess safety through funding provided by National Institute of Allergy and Infectious Diseases (NIAID).

XOMA is pursuing additional opportunities to further broaden the preclinical product pipeline. These include internal discovery programs, product development collaborations with other pharmaceutical and biotechnology companies and evaluations of product in-licensing, in-kind product trades and acquisition opportunities.

The Company competes with Amgen, Inc., Biovitrum AB, Cytos Biotechnology AG, Eli Lilly and Company, Novartis AG, Regeneron Pharmaceuticals, Inc., Cangene Corporation, Emergent BioSolutions, Inc., Abbott Laboratories and Johnson & Johnson.

Transforming Antibody Therapeutics
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people’s lives.

Our cross functional teams use a battery of intellectual property and an integrated platform of antibody technologies and capabilities to engineer cutting-edge therapeutic antibodies.

Pioneering New Products
Our flagship product candidate, XOMA 052, is an anti-inflammatory antibody with the potential to treat diseases like diabetes by addressing disease mechanisms in unexpected – and potentially more powerful – new ways. Other drug candidates in our pipeline include biodefense agents designed to protect against natural, accidental or intentional human exposure to botulism. Through collaborations with major biopharmaceutical partners, we are developing additional antibodies with multi-indication potential.

A Trusted Partner
Global biotechnology and pharmaceutical companies turn to XOMA for our valued antibody technologies and capabilities. Licensing and development collaborations have yielded three XOMA-enabled products that have received marketing approval and provide XOMA with royalty revenues. XOMA also generates revenue by licensing its antibody technologies and libraries.